[CUBIC News] Bio Coffee Meetup Reviews



CAMBRIDGE, MASSACHUSETTS, MAY 31, 2022 — CUBIC hosted a Bridge 12 coffee event last week, bringing together five exceptional biotech companies to discuss how life science businesses determine their funding methods in the current global capital, political, and economic environment. Representatives from Fuhong Therapeutics, Regor Therapeutics, FUSION Bioventures, Kira Pharmaceuticals, and Qilu Pharmaceuticals attended the meeting. 


Bridge12, located at 245 Main Street, is CIC's China business hub, which offers a strong network, programming, and consulting services to help promising US startups unlock the path to China. It hosts a series of events, activities, and programs to engage collaborators and provide resources and networks to startups.


Due to the epidemic, the funding environment in the life sciences sector has changed. Many innovative projects and startups have encountered difficulties with current financing. The epidemic has also posed a challenge to the current investment environment. As a result, in this environment, businesses want a platform to discuss strategies and funding options with one another. CUBIC will organize frequent gatherings with industry professionals to discuss the current industry environment and development trend within this concept.


Event Host

CUBIC Inc. is an overseas branch of Thinkzone International. It is  a Boston-based company specializing in helping foreign companies break into the China market and scale up quickly. We are China growth experts and a necessary local resource to enable success in the China markets.



Fuhong Therapeutics is a fast-growing biopharmaceutical company focused on the discovery and development of novel medications for a variety of indications in oncology, autoimmune diseases, and other therapeutic areas. The company, based in Shanghai, has developed state-of-the-art R&D facilities in the Pudong New District. The Fuhong team in drug discovery and technology platforms has been actively advancing transformational drug candidates in their pipeline to satisfy the requirements of patients all over the world, led by renowned industrial specialists. Fuhong Therapeutics has also created a U.S.-based R&D center in the Boston area, a hotbed of biological research and medication discovery, to tap into the best talent pool and gain access to cutting-edge technologies. The company's goal is to provide novel therapeutics to people with unmet medical needs.


Regor Therapeutics’s current areas of interest include oncology, metabolic diseases and autoimmune diseases. By leveraging industry-leading core strength in CARD (Computer Accelerated Rational Discovery), Regor is committed to creating a highly efficient ecosystem for accelerated discovery of innovative therapeutic agents with differentiated therapeutic values for patients around the world. With a strong focus on excellence in pharmaceutical research and global competitiveness, the company aspires to build a world-class innovation engine that promotes a winning culture of scientific excellence, strong teamwork driven by results and delivery with shared accountability and successes.


FUSION Bioventures was founded in 2017 and is constantly creating value through strategic investments in early-stage innovative cutting-edge programs and technologies. The company invests novel discovery/IP from top academic institutions, founding team with technology looking for early funding, as well as platform companies looking to expand via newco creation. Fusion Bioventures brings early-stage programs with access to Fosun Pharma Resources, such as business & operations, wide range R&D resources & expertise, and shared facility & office space. With strategic manufacturing partnerships around the world, its parent business, Fosun Pharma USA Inc. delivers high-quality products that comply with international standards. 


Kira Pharmaceuticals is founded by world renowned experts in complement biology, pioneering the field and developing a pipeline of compelling therapies designed to achieve better, longer acting and targeted immune modulation across a range of diseases—while still preserving or minimizing impairment in the body’s ability to actively fight new pathogens.Kira Pharmaceuticals has designed its LOGIC (Lead identification, Optimization and attribute Generation, In vivo Confirmation) drug discovery platform to overcome the inherent challenges in complement drug discovery and develop a pipeline of first and potentially best-in-class therapies to improve the lives of patients.

Qilu Pharmaceuticals is the 1st Chinese company to obtain USFDA and EDQM approval for sterile APIs. Its finished formulations and APIs have been approved by USFDA, European Medicines Agency (EMA), Therapeutic Goods Administration (TGA) of Australia, Medicines and Healthcare products Regulatory Agency (MHRA) of UK, PMDA of Japan and other national regulatory authorities. Qilu currently has 12 subsidiaries, 10 manufacturing sites and over 23000 employees worldwide. It has always maintained an innovative development strategy guided by the market demand and is achieving its organic growth strategy utilizing a strong pool of 2000+ scientists spread across 5 R&D platforms based in the US (Seattle WA, Boston MA, San Francisco CA) and China (Shanghai, Jinan).